세계의 당뇨병성 망막증 시장 보고서(2025년)
Diabetic Retinopathy Global Market Report 2025
상품코드 : 1824370
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

당뇨병성 망막증 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년 연평균 복합 성장률(CAGR)은 7.8%를 나타내 125억 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의료 접근법, 원격 의료 서비스 확대, 새로운 치료 개입 개발, POC(Point-of-Care) 검사 채택, 원격 환자 모니터링에 기인합니다. 예측 기간의 주요 동향으로는 치료에 있어서의 정밀의료, 조기 발견과 예방에 대한 주목의 높아짐, 원격 안과 서비스의 성장, 유전자 치료 연구 증가, 망막 화상 기술의 계속적인 진보 등을 들 수 있습니다.

향후 5년간의 성장률 7.8%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 일본과 스웨덴에서 조달한 안저카메라와 인공지능(AI) 기반의 스크리닝 소프트웨어 비용을 높여 고위험 집단의 예방 의료비를 악화시킴으로써 미국 안과 클리닉에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

당뇨병의 유병률 증가는 향후 당뇨병성 망막증 시장 성장을 이끌 것으로 예측됩니다. 당뇨병은 높은 혈당를 특징으로 하는 만성 대사성 질환입니다. 이 당뇨병 유병률의 상승은 과체중, 비만, 유전, 운동 부족 등의 요인에 크게 영향을 받고 있습니다. 고혈당은 빛을 감지하고 눈 안쪽의 신경을 통해 뇌로 신호를 보내는 역할을 하는 눈 부분인 망막을 손상시킬 수 있습니다. 예를 들어, 영국 정부 기관인 Office for Health Improvement and Disparities의 보고서에 따르면 2022년 3월부터 2023년 3월에 걸쳐 1형 당뇨병 환자 중 권장되는 8가지 케어 공정를 모두 받는 사람의 비율은 22% 증가했으며 2형 당뇨병에서는 21% 증가했습니다. 게다가 HbA1c의 목표치를 달성한 사람의 비율은 37.9%에 달했고, 전국 당뇨병 감사가 기록한 가운데 최고가 되었습니다. 이와 같이, 당뇨병 유병률 증가는 당뇨병성 망막증 시장 확대에 크게 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Diabetic retinopathy is a complication of diabetes that impacts the retina, the light-sensitive tissue at the back of the eye. It occurs due to damage to the blood vessels caused by prolonged high blood sugar levels. If not properly managed, this condition can lead to vision loss and even blindness, underscoring the importance of regular eye examinations for early detection and treatment.

The primary types of diabetic retinopathy include proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Proliferative diabetic retinopathy represents the advanced stage characterized by the emergence of abnormal new blood vessels on the surface of the retina. Various treatment modalities, such as anti-VEGF drugs, intraocular steroid injections, laser photocoagulation, and vitreoretinal surgery, are employed in settings such as hospitals, ambulatory surgical centers, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides diabetic retinopathy market statistics, including diabetic retinopathy industry global market size, regional shares, competitors with a diabetic retinopathy market share, detailed diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic retinopathy industry. This diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic retinopathy market size has grown strongly in recent years. It will grow from $8.61 billion in 2024 to $9.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, growing awareness about diabetic retinopathy, improved healthcare infrastructure, rising healthcare expenditure.

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $12.5 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approaches, expansion of telemedicine services, development of novel therapeutic interventions, adoption of point-of-care testing, remote patient monitoring. Major trends in the forecast period include precision medicine in diabetic retinopathy treatment, increased focus on early detection and prevention, teleophthalmology services growth, rise in gene therapy research, continuous advancements in retinal imaging technology.

The forecast of 7.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. eye clinics by driving up the cost of fundus cameras and Artificial intelligence(AI)-based screening software sourced from Japan and Sweden, exacerbating preventive care expenses for high-risk populations. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of diabetes is expected to drive the growth of the diabetic retinopathy market in the future. Diabetes is a chronic metabolic disease characterized by high blood glucose levels. This rise in diabetes prevalence is largely influenced by factors such as overweight, obesity, genetics, and physical inactivity. High blood sugar levels can damage the retina, the part of the eye responsible for detecting light and sending signals to the brain through a nerve at the back of the eye. For example, a report from the Office for Health Improvement and Disparities, a UK government department, indicated that from March 2022 to March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while type 2 diabetes saw a 21% rise. Additionally, the proportion of people achieving target HbA1c levels reached 37.9%, the highest recorded by the National Diabetes Audit. Thus, the growing prevalence of diabetes is significantly contributing to the expansion of the diabetic retinopathy market.

The increasing proportion of aging individuals is anticipated to drive the growth of the diabetic retinopathy market in the future. Aging individuals refer to those who are progressing in age and experiencing the effects of aging. This process is associated with a heightened susceptibility to chronic conditions, such as diabetes, which raises the risk and enlarges the population vulnerable to diabetic retinopathy. For instance, a report from the World Health Organization, a Switzerland-based agency, indicated that by 2050, 80% of older individuals are expected to live in low- and middle-income countries. By 2030, one in six people worldwide will be aged 60 years or older, significantly increasing the proportion of the population in this age group. Furthermore, the global population of individuals aged 60 and older is projected to double by 2050, reaching 2.1 billion. Therefore, the growing proportion of aging individuals is contributing to the expansion of the diabetic retinopathy market.

Technological advancements represent a prominent trend gaining traction in the diabetic retinopathy market. Major companies within this market are embracing innovative technologies to maintain their competitive standing. For instance, in July 2022, Baxter International Inc., a US-based healthcare company, introduced the Welch Allyn RetinaVue 100 Imager PRO in South Korea. These cutting-edge technologies aim to facilitate the detection of diabetic retinopathy in primary care settings, streamlining the process for annual diabetic retinal exams (DREs) during routine primary care visits and enhancing patient compliance.

Companies operating in the diabetic retinopathy market are strategically entering partnerships to enhance their market profitability. Collaborations in the context of diabetic retinopathy involve coordinated efforts among diverse stakeholders, including healthcare providers, researchers, pharmaceutical companies, and advocacy groups, to address challenges associated with diabetic retinopathy. For example, in October 2023, AEYE Health, a US-based provider of AI-based diagnostics for retinal imaging, joined forces with Topcon Screen, a Japan-based diabetic screening platform. Their collaboration aims to offer point-of-care screening for diabetic retinopathy using artificial intelligence, ensuring swift and precise results. This approach enables primary care clinicians to conduct diabetic retinopathy screenings directly in their clinics, reducing non-compliance risks and addressing care gaps associated with diabetic retinopathy screening through immediate and accurate assessments at the point of care.

In January 2022, Meteda, a US-based healthcare technology company, completed the acquisition of Retmarker SA for an undisclosed amount. Through this strategic move, Meteda seeks to broaden its access to periodic screening for diabetic retinopathy, utilize AI to address various diabetes-related issues, and strengthen its position in the EMEA region. Retmarker SA, based in Portugal, is an AI technology company specializing in ophthalmology, particularly focusing on retinal conditions such as diabetic retinopathy.

Major companies operating in the diabetic retinopathy market include Pfizer Inc., F-Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Oxurion NV, Graybug Vision Inc., Ampio Pharmaceuticals Inc.

North America was the largest region in the diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic retinopathy market includes revenues earned by entities by providing ophthalmologic examination, eye management and retinal imaging and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Retinopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic retinopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for diabetic retinopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic retinopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Diabetic Retinopathy Market Characteristics

3. Diabetic Retinopathy Market Trends And Strategies

4. Diabetic Retinopathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Diabetic Retinopathy Growth Analysis And Strategic Analysis Framework

6. Diabetic Retinopathy Market Segmentation

7. Diabetic Retinopathy Market Regional And Country Analysis

8. Asia-Pacific Diabetic Retinopathy Market

9. China Diabetic Retinopathy Market

10. India Diabetic Retinopathy Market

11. Japan Diabetic Retinopathy Market

12. Australia Diabetic Retinopathy Market

13. Indonesia Diabetic Retinopathy Market

14. South Korea Diabetic Retinopathy Market

15. Western Europe Diabetic Retinopathy Market

16. UK Diabetic Retinopathy Market

17. Germany Diabetic Retinopathy Market

18. France Diabetic Retinopathy Market

19. Italy Diabetic Retinopathy Market

20. Spain Diabetic Retinopathy Market

21. Eastern Europe Diabetic Retinopathy Market

22. Russia Diabetic Retinopathy Market

23. North America Diabetic Retinopathy Market

24. USA Diabetic Retinopathy Market

25. Canada Diabetic Retinopathy Market

26. South America Diabetic Retinopathy Market

27. Brazil Diabetic Retinopathy Market

28. Middle East Diabetic Retinopathy Market

29. Africa Diabetic Retinopathy Market

30. Diabetic Retinopathy Market Competitive Landscape And Company Profiles

31. Diabetic Retinopathy Market Other Major And Innovative Companies

32. Global Diabetic Retinopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Retinopathy Market

34. Recent Developments In The Diabetic Retinopathy Market

35. Diabetic Retinopathy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기